무료황금성 _ 68.rak136.top _ 무료슬롯머신777
페이지 정보
작성자 교혜오외 작성일25-09-18 19:27 조회0회 댓글0건관련링크
-
http://63.rsg385.top
0회 연결
-
http://23.rbq651.top
0회 연결
본문
【48.rak136.top】
[Kim Saemi, Edaily Reporter] On Sept. 15, Korea’s biotech and healthcare sector saw sharp moves, led by PROTEINA CO., LTD. (Proteina), a protein- protein interaction (PPI) big data company, which soared 26.28% to close at 30,150 won. HansBiomed Corporation (HansBioMed) jump 개인회생절차개시결정 ed more than 20%, while L&C BIO Co., LTD. (L&C Bio) and Bio Plus Co., Ltd. (BioPlus) also gained, drawing investor attention to next-generation skin booster makers. By contrast, Syntekabio, Inc. (Synt 서울보증보험연체자 ekabio) plunged on concerns over a planned rights offering.
Top Gainers on KOSDAQ, Sept. 15 (Source: KG Zeroin MP Doctor, formerly Market Point)
30만원대출
Investor Frenzy for Post-Rejuran Skin Boosters
Shares of HansBiomed, L&C Bio, and BioPlus-companies rolling out novel skin boosters-spiked in 새마을금고중앙회 자소서 첨삭 tandem. HansBioMed led the rally, finishing at 14,320 won, up 2,600 won (22.18%), according to KG Zeroin’s MP Doctor platform. L&C Bio advanced 9.11%, while BioPlus added 7.14%.
HansBioMed p 미소금융중앙재단 lans to officially launch its extracellular matrix (ECM)-based skin booster CellREDM™ on Sept. 29. Unlike existing skin boosters such as Rejuran, which stimulate collagen production by improving the skin’s environment, CellREDM directly replenishes collagen using human acellular dermal matrix (hADM). The product features ultra-fine 75 μm particles designed to deliver collagen more evenly and richly.
HansBioMed is not the first mover in hADM-based skin boosters. L&C Bio launched Re2O, the world’s first hADM-based skin booster, in Korea last November. Re2O surpassed 1,000 domestic client accounts as of last month and even saw temporary sell-outs on social media, fueling its stock rally. L&C Bio is building an additional production facility for Re2O, aiming for regulatory approval by year-end.
BioPlus, meanwhile, has developed a topical cell booster, Shine+Aura, using its proprietary Anti-Ubiquitination Technology (AUT) to block protein degradation and Bio-Material Transdermal System (BMTS) to improve skin penetration. This enables large-molecule growth factors to permeate deep into the skin. The product incorporates HUGRO, a new ingredient brand combining growth factors such as EGF and IGF with BioPlus’s patented technologies.
“Investors are increasingly searching for a ‘post-Rejuran’ opportunity, fueling interest in differentiated skin boosters,” said a healthcare industry source. “While Rejuran pioneered the market, newcomers are seeking to capture share with novel mechanisms.”
Proteina Rebounds Above 30,000 Won Despite Overhang Risks
Proteina surged 6,350 won (26.68%) to close at 30,150 won. At one point during intraday trading, the stock hit the upper limit of 30,900 won, up 29.83%, before easing back in late afternoon.
The company specializes in analyzing PPI through its SPID (single protein interaction detection) platform, quantifying molecular interactions and applying them to drug discovery. Building on its proprietary data, Proteina aims to become the global leader in AI-driven drug candidate identification.
Proteina went public on the KOSDAQ on July 29 via the tech-special listing route. Its shares more than doubled from the IPO price of 14,000 won, but volatility has increased amid overhang concerns. LB Investment cut its stake from 7.98% to 6.22% on Aug. 8, followed by JPMorgan Asset Management trimming from 5.16% to 2.89% on Aug. 10. Additional lock-up expirations loom?1.5 million shares on Sept. 29 and about 2 million on Oct. 29.
Despite these headwinds, Proteina rebounded from the 23,000 won range last week to reclaim the 30,000 won level. Its market capitalization now stands at 327.8 billion won. “We believe the market sees the valuation as still undervalued,” a company official said.
Syntekabio Plunges on $24M Rights Offering Plan
Syntekabio tumbled 1,080 won (19.89%) to 4,350 won, making it the worst performer on KOSDAQ, after announcing a large-scale rights issue. The company plans to raise 32.3 billion won ($24 million) through a shareholder-allotted public offering?the largest capital increase since its founding. The allocation ratio is 0.59 new shares per existing share.
The top decliner on KOSDAQ on Sept. 15 was Syntekabio. (Source: KG Zeroin MP Doctor)
Of the proceeds, 18.7 billion won will go toward debt repayment, 11.3 billion won to working capital, and 2.3 billion won to facilities. With outstanding bonds totaling 18.7 billion won, the company expects the capital raise to improve its financial structure.
Syntekabio said the rights offering aims to secure long-term growth capacity rather than short-term liquidity, positioning itself as a globally competitive AI drug discovery firm. “This rights issue is about enhancing corporate value in the long run, not just meeting immediate liquidity needs,” a company official said. “We are already generating revenue from contracts with domestic and international partners and expect to deliver stronger results next year.”
김새미 (bird@edaily.co.kr)
10원 야마토게임 _ 79.rak136.top _ 릴게임환전
슬롯게임 하는법 _ 75.rak136.top _ 바다이야기하는법
릴게임 코리아 _ 92.rak136.top _ 파칭코 어플
이벤트릴게임 _ 41.rak136.top _ 체리게임바둑이
바로가기 go !! 바로가기 go !!
신천지 오션파라다이스7 오락실슬롯머신 알라딘게임예시 오션슬롯먹튀 인터넷야마토게임 무료 충전 바다이야기 일본빠찡꼬 릴게임5만 황금성다운로드 릴게임뜻 바다이야기다운로드 잭팟 야마토2다운로드 야마토다운로드 릴게임매장 슬롯 확률 바다이야기 디시 오리지날황금성9게임 바다이야기꽁머니환전윈윈 바다이야기게임하는곳 온라인오션파라다이스 야마토 빠칭코 바다이야기고래출현 모바일야마토게임 릴게임 코리아 체리마스터 비법 오션파라다이스 릴 야마토 사설경정 우주전함야마토먹튀 릴게임안전사이트 릴게임5만 뉴야마토 무료 바다이야기 신천지 무료게임 야마토게임장주소 sp야마토 바다신2게임 슬롯머신 게임 야마토3게임다운로드후기 소액 슬롯 추천 최신릴게임 일본빠칭코게임 온라인바다이야기 우주 전함 야마토 2205 손오공 게임 무료야마토게임 바다이야기무료머니 오션릴게임 모바일신천지모바일 예시 무료슬롯사이트 릴게임환전 모바일파칭코 바다이야기환전가능 릴게임 코리아 종합 릴게임 무료백경 오션파라다이스 다운 체리게임바둑이 백경다운로드 사이다 릴게임 오션슬롯 황금성하는법 바다이야기 예시 황금성하는법 슬롯릴게임 야마토3 백경다운로드 뽀빠이놀이터릴게임 릴게임다빈치 무료슬롯버프 야마토게임동영상 우주전함야마토2199 사이다 릴게임 다모아릴게임 손오공게임 바다이야기사이트 오션파라다이스게임다운로드 황금성사이트 온라인 손오공 릴게임 안전 슬롯사이트 슬롯머신 사이트 황금성 게임 무료야마토게임 유희왕황금성 바다이야기 사이트 바다이야기코드 황금성게임앱 슬롯머신게임 바다신2게임 릴게임 사이트 도메인 릴게임먹튀검증 방법 오공슬롯 바다이야기 릴게임 무료게임 온라인야마토2 황금성검증 릴게임바다이야기 야마토2 pc버전 로드할 오션파라 다이스하는방법 바다게임 온라인룰렛 씨엔조이 릴게임 신천지게임 하는곳 릴게임 먹튀보증 릴게임이벤트 릴게임사이트 바다이야기 꽁머니 알라딘게임잭팟 모바일릴게임 슬롯나라 알라딘온라인릴게임 바다이야기 무료게임 창공릴게임 바다이야기무료체험 바다슬롯먹튀 메가슬롯 황금성동영상 백경게임랜드 바다이야기 고래 사설배팅 스핀모바게임랜드 This article was released as Pharm Edaily Premium Content on September 16, 2025, at 8:00 AM.[Kim Saemi, Edaily Reporter] On Sept. 15, Korea’s biotech and healthcare sector saw sharp moves, led by PROTEINA CO., LTD. (Proteina), a protein- protein interaction (PPI) big data company, which soared 26.28% to close at 30,150 won. HansBiomed Corporation (HansBioMed) jump 개인회생절차개시결정 ed more than 20%, while L&C BIO Co., LTD. (L&C Bio) and Bio Plus Co., Ltd. (BioPlus) also gained, drawing investor attention to next-generation skin booster makers. By contrast, Syntekabio, Inc. (Synt 서울보증보험연체자 ekabio) plunged on concerns over a planned rights offering.
Top Gainers on KOSDAQ, Sept. 15 (Source: KG Zeroin MP Doctor, formerly Market Point)
30만원대출
Investor Frenzy for Post-Rejuran Skin Boosters
Shares of HansBiomed, L&C Bio, and BioPlus-companies rolling out novel skin boosters-spiked in 새마을금고중앙회 자소서 첨삭 tandem. HansBioMed led the rally, finishing at 14,320 won, up 2,600 won (22.18%), according to KG Zeroin’s MP Doctor platform. L&C Bio advanced 9.11%, while BioPlus added 7.14%.
HansBioMed p 미소금융중앙재단 lans to officially launch its extracellular matrix (ECM)-based skin booster CellREDM™ on Sept. 29. Unlike existing skin boosters such as Rejuran, which stimulate collagen production by improving the skin’s environment, CellREDM directly replenishes collagen using human acellular dermal matrix (hADM). The product features ultra-fine 75 μm particles designed to deliver collagen more evenly and richly.
HansBioMed is not the first mover in hADM-based skin boosters. L&C Bio launched Re2O, the world’s first hADM-based skin booster, in Korea last November. Re2O surpassed 1,000 domestic client accounts as of last month and even saw temporary sell-outs on social media, fueling its stock rally. L&C Bio is building an additional production facility for Re2O, aiming for regulatory approval by year-end.
BioPlus, meanwhile, has developed a topical cell booster, Shine+Aura, using its proprietary Anti-Ubiquitination Technology (AUT) to block protein degradation and Bio-Material Transdermal System (BMTS) to improve skin penetration. This enables large-molecule growth factors to permeate deep into the skin. The product incorporates HUGRO, a new ingredient brand combining growth factors such as EGF and IGF with BioPlus’s patented technologies.
“Investors are increasingly searching for a ‘post-Rejuran’ opportunity, fueling interest in differentiated skin boosters,” said a healthcare industry source. “While Rejuran pioneered the market, newcomers are seeking to capture share with novel mechanisms.”
Proteina Rebounds Above 30,000 Won Despite Overhang Risks
Proteina surged 6,350 won (26.68%) to close at 30,150 won. At one point during intraday trading, the stock hit the upper limit of 30,900 won, up 29.83%, before easing back in late afternoon.
The company specializes in analyzing PPI through its SPID (single protein interaction detection) platform, quantifying molecular interactions and applying them to drug discovery. Building on its proprietary data, Proteina aims to become the global leader in AI-driven drug candidate identification.
Proteina went public on the KOSDAQ on July 29 via the tech-special listing route. Its shares more than doubled from the IPO price of 14,000 won, but volatility has increased amid overhang concerns. LB Investment cut its stake from 7.98% to 6.22% on Aug. 8, followed by JPMorgan Asset Management trimming from 5.16% to 2.89% on Aug. 10. Additional lock-up expirations loom?1.5 million shares on Sept. 29 and about 2 million on Oct. 29.
Despite these headwinds, Proteina rebounded from the 23,000 won range last week to reclaim the 30,000 won level. Its market capitalization now stands at 327.8 billion won. “We believe the market sees the valuation as still undervalued,” a company official said.
Syntekabio Plunges on $24M Rights Offering Plan
Syntekabio tumbled 1,080 won (19.89%) to 4,350 won, making it the worst performer on KOSDAQ, after announcing a large-scale rights issue. The company plans to raise 32.3 billion won ($24 million) through a shareholder-allotted public offering?the largest capital increase since its founding. The allocation ratio is 0.59 new shares per existing share.
The top decliner on KOSDAQ on Sept. 15 was Syntekabio. (Source: KG Zeroin MP Doctor)
Of the proceeds, 18.7 billion won will go toward debt repayment, 11.3 billion won to working capital, and 2.3 billion won to facilities. With outstanding bonds totaling 18.7 billion won, the company expects the capital raise to improve its financial structure.
Syntekabio said the rights offering aims to secure long-term growth capacity rather than short-term liquidity, positioning itself as a globally competitive AI drug discovery firm. “This rights issue is about enhancing corporate value in the long run, not just meeting immediate liquidity needs,” a company official said. “We are already generating revenue from contracts with domestic and international partners and expect to deliver stronger results next year.”
김새미 (bird@edaily.co.kr)
댓글목록
등록된 댓글이 없습니다.
